Compare GOSS & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | OCCI |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 120.2M |
| IPO Year | 2018 | N/A |
| Metric | GOSS | OCCI |
|---|---|---|
| Price | $0.34 | $2.73 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 17.6M | 352.8K |
| Earning Date | 03-17-2026 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $147.82 | $10.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.32 | $2.62 |
| 52 Week High | $3.87 | $6.82 |
| Indicator | GOSS | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 30.71 |
| Support Level | $0.33 | N/A |
| Resistance Level | $0.60 | $3.07 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 19.69 | 25.82 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.